Nehete PN - Search Results

1

Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates.

Pons-Faudoa FP, Sizovs A, Shelton KA, Momin Z, Niles JA, Bushman LR, Xu J, Chua CYX, Nichols JE, Demaria S, Ittmann MM, Hawkins T, Rooney JF, Marzinke MA, Kimata JT, Anderson PL, Nehete PN, Arduino RC, Ferrari M, Sastry KJ, Grattoni A. Pons-Faudoa FP, et al. Among authors: nehete pn. Adv Ther (Weinh). 2021 Mar;4(3):2000163. doi: 10.1002/adtp.202000163. Epub 2020 Dec 16. Adv Ther (Weinh). 2021. PMID: 33997267 Free PMC article.

2

Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120.

Sastry KJ, Nehete PN, Venkatnarayanan S, Morkowski J, Platsoucas CD, Arlinghaus RB. Sastry KJ, et al. Among authors: nehete pn. Virology. 1992 Jun;188(2):502-9. doi: 10.1016/0042-6822(92)90504-i. Virology. 1992. PMID: 1316670

3

Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response.

Nehete PN, Arlinghaus RB, Sastry KJ. Nehete PN, et al. Viral Immunol. 1994;7(4):189-97. doi: 10.1089/vim.1994.7.189. Viral Immunol. 1994. PMID: 7576033

4

Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1.

Casement KS, Nehete PN, Arlinghaus RB, Sastry KJ. Casement KS, et al. Among authors: nehete pn. Virology. 1995 Aug 1;211(1):261-7. doi: 10.1006/viro.1995.1399. Virology. 1995. PMID: 7645219 Free article.

5

Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB.

Nehete PN, Murthy KK, Satterfield WC, Arlinghaus RB, Sastry KJ. Nehete PN, et al. AIDS. 1995 Jun;9(6):567-72. doi: 10.1097/00002030-199506000-00006. AIDS. 1995. PMID: 7662194

6

Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.

Nehete PN, Arlinghaus RB, Sastry KJ. Nehete PN, et al. J Virol. 1993 Nov;67(11):6841-6. doi: 10.1128/JVI.67.11.6841-6846.1993. J Virol. 1993. PMID: 7692087 Free PMC article.

7

Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.

Nehete PN, Casement KS, Arlinghaus RB, Sastry KJ. Nehete PN, et al. Cell Immunol. 1995 Feb;160(2):217-23. doi: 10.1016/0008-8749(95)80031-d. Cell Immunol. 1995. PMID: 7720083

8

Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160.

Nehete PN, Satterfield WC, Matherne CM, Arlinghaus RB, Sastry KJ. Nehete PN, et al. AIDS Res Hum Retroviruses. 1993 Mar;9(3):235-40. doi: 10.1089/aid.1993.9.235. AIDS Res Hum Retroviruses. 1993. PMID: 8471313

9

Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.

Nehete PN, Johnson PC, Schapiro SJ, Arlinghaus RB, Sastry KJ. Nehete PN, et al. J Clin Immunol. 1996 Mar;16(2):115-24. doi: 10.1007/BF01540958. J Clin Immunol. 1996. PMID: 8690775

10

Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells.

Sastry KJ, Marin MC, Nehete PN, McConnell K, el-Naggar AK, McDonnell TJ. Sastry KJ, et al. Among authors: nehete pn. Oncogene. 1996 Aug 1;13(3):487-93. Oncogene. 1996. PMID: 8760290

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page